WALVAX(SZ:300142) Zheng Quan Zhi Xing·2025-08-03 16:18Core Viewpoint - Yunnan Watson Bio's application for clinical trials of its respiratory syncytial virus mRNA vaccine has been accepted by the National Medical Products Administration, marking a significant step in its development [1][2]. Group 1: Company Information - The vaccine is developed in collaboration with Fudan University, Shanghai Bluebird Biomedicine Co., Ltd., and its subsidiaries, aiming to stimulate immune responses against respiratory syncytial virus (RSV) [2]. - The vaccine is classified as a preventive biological product under the registration category 1.2 [1]. Group 2: Industry Context - Three RSV vaccines have been approved and are currently available in foreign markets, including GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA, with global sales reaching approximately $4 billion [2]. - The acceptance of the clinical trial application does not significantly impact the company's operating performance for the current year [2].